Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?

Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer’s disease biomarkers in many clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic value. Twenty patients from a cognitive clinic, who had undergone...

Descripción completa

Detalles Bibliográficos
Autores principales: Weston, Philip S.J., Paterson, Ross W., Dickson, John, Barnes, Anna, Bomanji, Jamshed B., Kayani, Irfan, Lunn, Michael P., Mummery, Catherine J., Warren, Jason D., Rossor, Martin N., Fox, Nick C., Zetterberg, Henrik, Schott, Jonathan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181662/
https://www.ncbi.nlm.nih.gov/pubmed/27567830
http://dx.doi.org/10.3233/JAD-160302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181662/
https://www.ncbi.nlm.nih.gov/pubmed/27567830
http://dx.doi.org/10.3233/JAD-160302

Ejemplares similares